Cadence completes acquisition of OpenEye Scientific Software for drug discovery software

CADENCE DESIGN SYSTEMS INC

Acquisition of OpenEye Scientific Software closed on August 31, 2022.
OpenEye provides computational molecular modeling and simulation software for drug discovery.
Funded by cash on hand and borrowings under Cadence's senior unsecured revolving credit facility.
No purchase price or financial guidance disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.